Shionogi

Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

  • by

Shots: Shionogi to receive an up front, milestones as well as royalties on sales of the therapy. BioAge to get exclusive US and EU rights to develop and commercialize BGE-17 for COVID-19 Additionally, BioAge gets an exclusive right to negotiate a license for additional indications… Read More »Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

Shionogi and Nagasaki University Collaborate with the Kitasato Institute for Antimalarial Drugs

  • by

Shots: Kitasato & Shionogi-Nagasaki will collaborate on the R&D of the new antimalarial natural products discovered by Ōmura Satoshi Memorial Institute for the antimalarial drugs The collaboration accelerates the research for antimalarial drugs & vaccines by fostering an open innovation platform merging the strengths of… Read More »Shionogi and Nagasaki University Collaborate with the Kitasato Institute for Antimalarial Drugs

Shionogi Receives MHLW’s Approval for Xofluza’s sNDA to Treat Post-Exposure Prophylaxis of Influenza Virus Infection

  • by

Shots: The approval is based on P-III BLOCKSTONE study assessing Xofluza (baloxavir marboxil, 10/20mg) vs PBO in patients in household members aged ≥12yrs. who was living with someone with an influenza infection confirmed by a rapid influenza diagnostic test Result: The proportion of household members… Read More »Shionogi Receives MHLW’s Approval for Xofluza’s sNDA to Treat Post-Exposure Prophylaxis of Influenza Virus Infection